Name: Relias Media
Price range: $

Functional Cognitive Disorder: An Important Condition to Recognize

Functional cognitive disorder (FCD) can describe cognitive difficulties that are present where there is no biologic cause, but a lack of consensus in diagnostic criteria limits its use in clinical practice and research. The authors proposed an operational definition for FCD as the cognitive phenotype of functional neurological disorder.

Statins, Cognitive Decline, and Dementia

An analysis of the ASPREE database showed that with almost five years of follow-up, statins are not associated with cognitive decline or dementia in a large group of elderly subjects in whom multiple tests of cognition were performed serially.

Researchers Find Lower Amyloid Levels in Patients on Blood Sugar Control Drug

An investigation reveals an interesting trait among those taking a common diabetes management solution.

Anticholinergic Use for Three Months or More Increases Dementia Risk

There is a significant increase in dementia risk associated with the use of anticholinergic medications for three months or longer.

Underrepresented Groups in Alzheimer’s Trials Remain Persistent Ethical Concern

Despite ongoing efforts to address disparities in Alzheimer’s disease and dementia care, much work remains. The authors of a recent report identified some of the barriers diverse populations are facing in accessing and receiving dementia care.

Ethical Controversy Erupts Over Alzheimer’s Drug Approval

The first new Alzheimer’s drug to be approved in almost 20 years has sparked a major ethical controversy, leading to protest resignations, criticism, qualifying statements, and even calls for investigations.

Statins, Cognitive Decline, and Dementia

An analysis of the ASPREE database showed that with almost five years of follow-up, statins are not associated with cognitive decline or dementia in a large group of elderly subjects in whom multiple tests of cognition were performed serially.

Long-Term Effects of Cholinesterase Inhibitors on Cognitive Decline, Mortality

Cholinesterase inhibitors are one of the few drug classes approved by the FDA to treat patients with Alzheimer’s disease. This study shows a long-term benefit in slowing the decline of cognition, but it is unclear if there is any benefit in quality of life.